{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:28:46Z","timestamp":1790234926305,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"51","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Korean Healthcare Technology R&D Project, Ministry for Health, Welfare and Family Affairs, Republic of Korea","award":["HI13C0016"],"award-info":[{"award-number":["HI13C0016"]}]},{"DOI":"10.13039\/501100005006","name":"Asan Institute for Life Sciences, Asan Medical Center","doi-asserted-by":"publisher","award":["2016-678"],"award-info":[{"award-number":["2016-678"]}],"id":[{"id":"10.13039\/501100005006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2016R1C1B1014775"],"award-info":[{"award-number":["NRF-2016R1C1B1014775"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Science, ICT & Future Planning"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.vaccine.2016.11.008","type":"journal-article","created":{"date-parts":[[2016,11,18]],"date-time":"2016-11-18T04:01:10Z","timestamp":1479441670000},"page":"6472-6480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Modular virus-like particles for sublingual vaccination against group A streptococcus"],"prefix":"10.1016","volume":"34","author":[{"given":"Arjun","family":"Seth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Il Gyu","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Young","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Soo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeji","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nani","family":"Wibowo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton P.J.","family":"Middelberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda H.L.","family":"Lua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi-Na","family":"Kweon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.11.008_b0005","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(05)70267-X","article-title":"The global burden of group A streptococcal diseases","volume":"5","author":"Carapetis","year":"2005","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.vaccine.2016.11.008_b0010","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00109-012-0897-9","article-title":"Conserved anchorless surface proteins as group A streptococcal vaccine candidates","volume":"90","author":"Henningham","year":"2012","journal-title":"J Mol Med"},{"key":"10.1016\/j.vaccine.2016.11.008_b0015","unstructured":"Dale JB, Batzloff MR, Cleary PP, Courtney HS, Good MF, Grandi G, et al. Current approaches to group A streptococcal vaccine development. In: Ferretti JJ, Stevens DL, Fischetti VA, editors. Streptococcus pyogenes: Basic Biology to Clinical Manifestations. Oklahoma City (OK) 2016."},{"key":"10.1016\/j.vaccine.2016.11.008_b0020","first-page":"207","article-title":"Group a streptococcal vaccine candidates: potential for the development of a human vaccine","volume":"368","author":"Henningham","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2016.11.008_b0025","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1586\/14760584.3.1.43","article-title":"Lipid core peptide technology and group A streptococcal vaccine delivery","volume":"3","author":"Olive","year":"2004","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2016.11.008_b0030","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0140-6736(94)92083-4","article-title":"Towards a vaccine for rheumatic fever: identification of a conserved target epitope on M protein of group A streptococci","volume":"344","author":"Pruksakorn","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.11.008_b0035","first-page":"12","article-title":"Mapping a conserved conformational epitope from the M protein of group A streptococci","volume":"9","author":"Relf","year":"1995","journal-title":"Pept Res"},{"key":"10.1016\/j.vaccine.2016.11.008_b0040","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1046\/j.1365-2567.1996.d01-754.x","article-title":"Opsonic human antibodies from an endemic population specific for a conserved epitope on the M protein of group A streptococci","volume":"89","author":"Brandt","year":"1996","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2016.11.008_b0045","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/S0264-410X(97)00178-3","article-title":"Human antibodies to the conserved region of the M protein: opsonization of heterologous strains of group A streptococci","volume":"15","author":"Brandt","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.11.008_b0050","doi-asserted-by":"crossref","first-page":"7154","DOI":"10.1016\/j.vaccine.2011.05.075","article-title":"A microbial platform for rapid and low-cost virus-like particle and capsomere vaccines","volume":"29","author":"Middelberg","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.11.008_b0055","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0966-842X(03)00208-7","article-title":"Virus-like particles as immunogens","volume":"11","author":"Noad","year":"2003","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.vaccine.2016.11.008_b0060","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1586\/erv.10.115","article-title":"Virus-like particles in vaccine development","volume":"9","author":"Roldao","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2016.11.008_b0065","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/bit.25172","article-title":"Microbially synthesized modular virus-like particles and capsomeres displaying group A streptococcus hypervariable antigenic determinants","volume":"111","author":"Chuan","year":"2014","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2016.11.008_b0070","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/491021a","article-title":"Hepatitis E vaccine debuts","volume":"491","author":"Park","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2016.11.008_b0075","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/0264-410X(90)90222-8","article-title":"Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine","volume":"8","author":"Andre","year":"1990","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.11.008_b0080","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2471\/BLT.06.038414","article-title":"Human papillomavirus and HPV vaccines: a review","volume":"85","author":"Cutts","year":"2007","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2016.11.008_b0085","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/wnan.119","article-title":"Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design","volume":"3","author":"Plummer","year":"2011","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"10.1016\/j.vaccine.2016.11.008_b0090","doi-asserted-by":"crossref","first-page":"e9809","DOI":"10.1371\/journal.pone.0009809","article-title":"Versatile virus-like particle carrier for epitope based vaccines","volume":"5","author":"Tissot","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.11.008_b0095","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ymeth.2006.07.018","article-title":"Virus-like particles: passport to immune recognition","volume":"40","author":"Grgacic","year":"2006","journal-title":"Methods"},{"key":"10.1016\/j.vaccine.2016.11.008_b0100","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1515\/BC.2008.064","article-title":"The coming of age of virus-like particle vaccines","volume":"389","author":"Jennings","year":"2008","journal-title":"Biol Chem"},{"key":"10.1016\/j.vaccine.2016.11.008_b0105","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/j.vaccine.2013.02.013","article-title":"Self-adjuvanting modular virus-like particles for mucosal vaccination against group A streptococcus (GAS)","volume":"31","author":"Rivera-Hernandez","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.11.008_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cyto.2010.12.014","article-title":"Sublingual mucosa: a new vaccination route for systemic and mucosal immunity","volume":"54","author":"Kweon","year":"2011","journal-title":"Cytokine"},{"key":"10.1016\/j.vaccine.2016.11.008_b0115","series-title":"Sublingual delivery of vaccines","author":"Lawson","year":"2011"},{"key":"10.1016\/j.vaccine.2016.11.008_b0120","doi-asserted-by":"crossref","first-page":"7851","DOI":"10.4049\/jimmunol.0803740","article-title":"Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection","volume":"183","author":"Cuburu","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2016.11.008_b0125","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0006-3495(93)81120-2","article-title":"Dehydration-induced conformational transitions in proteins and their inhibition by stabilizers","volume":"65","author":"Prestrelski","year":"1993","journal-title":"Biophys J"},{"key":"10.1016\/j.vaccine.2016.11.008_b0130","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1042\/BA20030133","article-title":"Freeze-drying of proteins: some emerging concerns","volume":"39","author":"Roy","year":"2004","journal-title":"Biotechnol Appl Biochem"},{"issue":"s1","key":"10.1016\/j.vaccine.2016.11.008_b0135","first-page":"93","article-title":"Efficacy and tolerability of sublingual fentanyl in opioid-tolerant cancer patients with breakthrough pain: interim findings from two long-term. Phase III multi-centre studies","volume":"9","author":"Rauck","year":"2009","journal-title":"Pain Pract"},{"key":"10.1016\/j.vaccine.2016.11.008_b0140","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1185\/03007990903368310","article-title":"Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain","volume":"25","author":"Rauck","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.vaccine.2016.11.008_b0145","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1002\/bit.21710","article-title":"Quantitative analysis of virus-like particle size and distribution by field-flow fractionation","volume":"99","author":"Chuan","year":"2008","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2016.11.008_b0150","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1098\/rsif.2009.0175","article-title":"Virus assembly occurs following a pH-or Ca2+-triggered switch in the thermodynamic attraction between structural protein capsomeres","volume":"7","author":"Chuan","year":"2009","journal-title":"J R Soc Interface"},{"key":"10.1016\/j.vaccine.2016.11.008_b0155","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ymeth.2013.04.019","article-title":"Virus-like particle formulation optimization by miniaturized high-throughput screening","volume":"60","author":"Mohr","year":"2013","journal-title":"Methods"},{"key":"10.1016\/j.vaccine.2016.11.008_b0160","doi-asserted-by":"crossref","first-page":"7154","DOI":"10.1016\/j.vaccine.2011.05.075","article-title":"A microbial platform for rapid and low-cost virus-like particle and capsomere vaccines","volume":"29","author":"Middelberg","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.11.008_b0165","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1086\/374800","article-title":"Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection","volume":"187","author":"Batzloff","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.11.008_b0170","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1086\/466528","article-title":"Toward the development of an antidisease, transmission-blocking intranasal vaccine for group a streptococcus","volume":"192","author":"Batzloff","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.11.008_b0175","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1002\/bit.24907","article-title":"Effects of pre-existing anti-carrier immunity and antigenic element multiplicity on efficacy of a modular virus-like particle vaccine","volume":"110","author":"Chuan","year":"2013","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2016.11.008_b0180","doi-asserted-by":"crossref","first-page":"6915","DOI":"10.1128\/IAI.71.12.6915-6920.2003","article-title":"Th1-directing adjuvants increase the immunogenicity of oligosaccharide-protein conjugate vaccines related to Streptococcus pneumoniae type 3","volume":"71","author":"Lefeber","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.11.008_b0185","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1002\/1521-4141(200208)32:8<2274::AID-IMMU2274>3.0.CO;2-C","article-title":"Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant","volume":"32","author":"BenMohamed","year":"2002","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2016.11.008_b0190","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1073\/pnas.0708684105","article-title":"Sublingual vaccination with influenza virus protects mice against lethal viral infection","volume":"105","author":"Song","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2016.11.008_b0195","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.it.2006.10.005","article-title":"Targeting dendritic cells with biomaterials: developing the next generation of vaccines","volume":"27","author":"Reddy","year":"2006","journal-title":"Trends Immunol"},{"key":"10.1016\/j.vaccine.2016.11.008_b0200","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/CJI.0b013e31818f13c4","article-title":"Virus-like particle (VLP) lymphatic trafficking and immune response generation after immunization by different routes","volume":"32","author":"Cubas","year":"2009","journal-title":"J Immunother"},{"key":"10.1016\/j.vaccine.2016.11.008_b0205","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1128\/IAI.72.5.2507-2512.2004","article-title":"Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections","volume":"72","author":"Hall","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.11.008_b0210","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1128\/IAI.65.6.2080-2087.1997","article-title":"Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by the group A streptococcus","volume":"65","author":"Ji","year":"1997","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.11.008_b0215","doi-asserted-by":"crossref","first-page":"7878","DOI":"10.1128\/IAI.73.12.7878-7886.2005","article-title":"Active and passive intranasal immunizations with streptococcal surface protein C5a peptidase prevent infection of murine nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils","volume":"73","author":"Park","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.11.008_b0220","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.tim.2010.02.007","article-title":"The streptococcal M protein: a highly versatile molecule","volume":"18","author":"Smeesters","year":"2010","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.vaccine.2016.11.008_b0225","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1473-3099(09)70178-1","article-title":"Global emm type distribution of group A streptococci: systematic review and implications for vaccine development","volume":"9","author":"Steer","year":"2009","journal-title":"Lancet Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16310398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16310398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T10:57:23Z","timestamp":1601204243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16310398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":45,"journal-issue":{"issue":"51","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0264410X16310398"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.11.008","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modular virus-like particles for sublingual vaccination against group A streptococcus","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}